|
Isolate
|
Culture
|
Clinical
|
Phenotypic resistance
|
Susceptibility
|
Mutations detected inc
|
embB
|
pncA
|
Spoligotyping
|
Final resistance
|
|---|
|
no.
|
no.
|
specimen
|
to anti-TB drugsb
|
to PZAb
|
rpoB
|
katG315
|
inhA-RR
|
mutation
|
mutation
|
lineage
|
pattern
|
|---|
|
D1
|
5853/05
|
BALa
|
INH + SM
|
Not done
|
H526N
|
S315 T
|
None
|
None
|
None
|
Orphan
|
INH + SM + RIF
|
|
D2
|
13,242/10
|
Sputum
|
INH + EMB
|
Not done
|
D516Y
|
S315 T
|
None
|
M306 V
|
R2Pd
|
EAI5/EAI3
|
INH + EMB + RIF + PZA
|
|
D3
|
10,268/11
|
Pleural fluid
|
INH + SM
|
Resistant
|
H526N
|
S315 T
|
None
|
M306 V
|
H51P
|
Orphan
|
INH + SM + PZA + RIF + EMB
|
|
D4
|
13,341/16
|
Sputum
|
INH + SM + EMB
|
Susceptible
|
S531C
|
S315 T
|
None
|
M306 V
|
None
|
T1 Uganda
|
INH + SM + EMB + RIF
|
- INH, isoniazid; SM, streptomycin; EMB, ethambutol; RIF, rifampicin, PZA, pyrazinamide
- HSR-rpoB, 81-base pair hot-spot region of rpoB gene; katG315, katG codon 315; inhA-RR, upstream regulatory region of inhA gene
- aBAL, bronchoalveolar lavage
- bThe susceptibility to anti-TB drugs was determined by MGIT 960 system
- cMutations in rpoB, katG codon 315 and inhA-regulatory region were detected by GenoType MTBDRplus assay and/or PCR-sequencing of respective loci
- dRepresents a novel mutation not described previously
